← Back to 25C-NBOH

25C-NBOH Stats & Data

Psychedelic Research-chemical

2c-c-nboh Nboh-2c-c

NPS DataHub

MW321.8

FormulaC17H20ClNO3

CAS1391488-16-6

IUPAC2-[[2-(4-chloro-2,5-dimethoxyphenyl)ethylamino]methyl]phenol

SMILESCOc1cc(CCNCc2ccccc2O)c(OC)cc1Cl

InChIKeyVHWXICYYQMMZCW-UHFFFAOYSA-N

Phenethylamines; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen

Chemical Class Phenethylamine

Psychoactive Class Psychedelic

Receptor Profile

Receptor Actions

Agonists

5-HT2A receptor agonist (potent, pEC50 9.43)

5-HT2C receptor agonist (pKi 7.8)

History & Culture

25C-NBOH was first synthesized and documented in 2011 by Martin Hansen at the University of Copenhagen. The compound is a derivative of the phenethylamine psychedelic 2C-C, distinguished by the addition of an N-benzyl group bearing a hydroxyl substituent on the benzyl ring. The substance has no documented history of human use prior to 2011, when it emerged on the online designer drug market shortly after its initial synthesis. It belongs to the NBOH (N-benzyl-2-hydroxybenzyl) series of phenethylamines, which are structurally related to the more widely known 25x-NBOMe compounds. Due to its recent development and limited formal research, documentation regarding its properties and effects in humans remains sparse.

Effect Profile

Curated + 4 Reports

Psychedelic 8.4

Strong visuals, auditory effects, body load, and headspace

Visual Intensity×3

Headspace Depth×3

Auditory Effects×1

Body Load / Somatic Effects×1

Based on reports from:

Erowid Experience Reports PsychonautWiki 25C-NBOH

Tolerance & Pharmacokinetics

drugs.wiki

Tolerance Decay

Full tolerance 1h Half tolerance 10d Baseline ~14d

Experience Report Analysis

Erowid

4 Reports

2013–2014 Date Range

4 With Age Data

1 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid

Effects aggregated from 4 experience reports (4 Erowid)

4 Reports

1 Effects Detected

0 Positive

0 Adverse

1 Neutral

Effect Sentiment Distribution

Confidence Distribution

Positive Effects 0

Adverse Effects 0

Real-World Dose Distribution

62K Doses

From 5 individual dose entries

Form / Preparation

Most common forms and preparations reported

Read full reports on Erowid →

Legal Status

Country	Status	Notes
Brazil	Controlled (Portaria SVS/MS nº 344)	Added to Portaria SVS/MS nº 344 on December 10, 2018, which is Brazil's regulatory framework for controlled substances. Possession, distribution, and use are prohibited under federal law.
Germany	NpSG (Controlled)	Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016. Production and importation with intent to market, administration to others, and commercial trading are criminally punishable. Possession is technically illegal but carries no criminal penalty.
Sweden	Schedule I (Narcotic)	Classified under Schedule I of the Narcotic Drugs Punishments Act since August 18, 2015, following action by the Riksdag. This scheduling applies to substances, plant materials, and fungi that normally have no accepted medical use. Published by the Medical Products Agency in regulation HSLF-FS 2015:12.
Switzerland	Controlled (Verzeichnis E)	Specifically named as a controlled substance under Verzeichnis E (Schedule E) of Swiss narcotics legislation. Unauthorized possession, production, and distribution are prohibited.
United Kingdom	Class A	Controlled as a Class A substance under the Misuse of Drugs Act 1971 through the N-benzylphenethylamine catch-all clause. Class A drugs carry the most severe penalties, including up to 7 years imprisonment for possession and life imprisonment for supply offenses.

References

Data Sources

Cited References

← Back to 25C-NBOH